AMP German Cannabis Group Enters into memorandum of understanding supply agreement for the import of EU-GMP medical cannabis into Germany

AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that it has entered into a non-binding memorandum of understanding to purchase up to 1,200 kilograms of either branded or white-labeled European Union – Good Manufacturing Practice (EU-GMP) medical cannabis flower annually from an Alberta based supplier with a cultivation and processing licence from Health Canada (“Alberta LP”).

AMP and the Alberta LP will begin imports upon the Alberta LP receiving a sales licence from Health Canada and receiving EU-GMP certification by German State officials.

EU-GMP certification is an internationally recognized system that ensures all pharmaceutical goods, including medical cannabis, meet the highest consumer health and safety standards. Canadian licensed producers of cannabis production and operating processes do not meet EU-GMP standards and need to be upgraded and receive EU-GMP certification from a German State before being able to export to Germany.

Management Quotes:

Mr. Alex Blodgett, CEO of AMP German Cannabis Group, commented, “Aurora Cannabis (NYSE: ACB), which was awarded a German cultivation license, and other small to medium sized cannabis producers have made the Alberta region into a major cannabis production cluster in Canada. This is AMP’s second supply agreement with an Alberta region supplier focused on supplying Germany with EU-GMP cannabis.”

Dr. Stefan Feuerstein, Managing Director of Alternative Medical Products GmbH (“AMP Germany”), commented, “AMP expects to close further supply agreements before year end in addition to receiving our narcotic license to import medical cannabis into Germany.”